These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 2512890)

  • 1. [Economic lessons of large-scale thrombolytic trials].
    Beaufils P; Blum-Boisgard C; Geffroy L; Hazebroucq G; Launois B; Launois R; Leclercq B; Viens-Bitker C
    Arch Mal Coeur Vaiss; 1989 Oct; 82 Spec No 3():63-8. PubMed ID: 2512890
    [No Abstract]   [Full Text] [Related]  

  • 2. [Methodologic and clinical lessons of large-scale trials of thrombolytic agents].
    Beaufils P; Boissel JP; Castaigne A; Cohen-Solal A; Slama M; Spriet A
    Arch Mal Coeur Vaiss; 1989 Oct; 82 Spec No 3():35-41. PubMed ID: 2512886
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 4. [Thrombolysis in stroke. An evaluation by the SBU Alert].
    Norrving DB; Britton DM; Asplund K
    Lakartidningen; 1999 Feb; 96(7):760-1. PubMed ID: 10087782
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cost-effectiveness of primary PTCA and thrombolysis in the treatment of acute myocardial infarction].
    Sagmeister M; Amann FW; Follath F
    Schweiz Med Wochenschr; 2000 Aug; 130(33):1146-51. PubMed ID: 11005104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
    Müllner M; Paulis M; Nikfardjam M; Domanovits H; Huber K
    Wien Klin Wochenschr; 1999 Jan; 111(1):37-41. PubMed ID: 10067269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombolytic therapy].
    de Gaetano G; Donati MB; Gensini GF; Restagno C
    Recenti Prog Med; 1993 Sep; 84(9):581-5. PubMed ID: 8210621
    [No Abstract]   [Full Text] [Related]  

  • 8. Using economics alongside clinical trials: why we cannot choose the evaluation technique in advance.
    Donaldson C; Hundley V; McIntosh E
    Health Econ; 1996; 5(3):267-9. PubMed ID: 8817300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the use of t-PA as compared with streptokinase cost effective?
    Armentano R; Favaloro RG
    N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of myocardial infarction in the elderly: admission and outcome on a coronary care unit.
    Haigh R; Castleden M; Woods K; Fletcher S; Bowns I; Gibson M; Soper J
    Health Trends; 1991-1992; 23(4):154-7. PubMed ID: 10117736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comments on the article "Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis" by Golán et al].
    Vlcek J
    Vnitr Lek; 2003 Feb; 49(2):87-8. PubMed ID: 12728569
    [No Abstract]   [Full Text] [Related]  

  • 12. [Acute myocardial infarct: thrombolysis of coronary angioplasty?].
    Rickenbacher P
    Praxis (Bern 1994); 1998 Feb; 87(6):183-5. PubMed ID: 9531811
    [No Abstract]   [Full Text] [Related]  

  • 13. Is a 3-day hospitalization cost-effective for patients after uncomplicated acute myocardial infarction (AMI)?
    Koenig C; Stevermer J
    J Fam Pract; 2000 Jun; 49(6):574. PubMed ID: 10923562
    [No Abstract]   [Full Text] [Related]  

  • 14. Hospital cost of acute myocardial infarction in the thrombolytic era.
    Mahon NG; Rahallaigh PO; O'Sullivan JB; Codd MB; McCann HA; Sugrue DD
    Ir Med J; 2000 Jun; 93(4):122. PubMed ID: 11037575
    [No Abstract]   [Full Text] [Related]  

  • 15. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients].
    Machecourt J; Cassagnes J; Bassand JP; Dumoulin J; Calop J; Foroni L; Terrisse MP; Hénon T; Petit L; Denis B
    Arch Mal Coeur Vaiss; 1993 Feb; 86(2):209-17. PubMed ID: 8363422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction.
    Selmer R; Halvorsen S; Myhre KI; Wisløff TF; Kristiansen IS
    Scand Cardiovasc J; 2005 Oct; 39(5):276-85. PubMed ID: 16269397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis in health care.
    Chalfin DB
    Hosp Cost Manag Account; 1995 Jul; 7(4):1-8. PubMed ID: 10143321
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian Consensus Conference on Coronary Thrombolysis--1994 update.
    Cairns J; Armstrong P; Belenkie I; Hirsh J; Johnstone D; Knudtson M; Lemieux M; Massel D; Naylor D; Roy L
    Can J Cardiol; 1994 Jun; 10(5):517-21. PubMed ID: 8012879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.